Evotec and Plectonic Collaborate on T-Cell Approaches for Solid Tumors

Evotec SE and Plectonic Biotech have announced a research collaboration to develop novel T-cell-engaging immunotherapies for solid tumors. This collaboration combines Plectonic's LOGIBODY® technology with Evotec’s BiTco platform, aiming to tackle challenges in current T-cell engager therapies for solid tumors.

Plectonic's LOGIBODY® utilizes programmable DNA-protein therapeutics to enhance tumor recognition through multi-antigen signatures, while Evotec’s BiTco platform provides costimulatory signals to boost T-cell activity. The synergy aims to improve the precision and potency of T-cell engagement, enhancing tumor targeting while minimizing effects on healthy tissues.

The collaboration will focus on generating preclinical proof-of-concept data, potentially broadening the therapeutic window. Both companies aim to assess if their combined technologies can achieve more effective and controlled T-cell activation against solid tumors.